Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Receivables (2016 - 2025)

Cardiff Oncology's Receivables history spans 15 years, with the latest figure at $482000.0 for Q4 2025.

  • For Q4 2025, Receivables fell 58.91% year-over-year to $482000.0; the TTM value through Dec 2025 reached $482000.0, down 58.91%, while the annual FY2025 figure was $482000.0, 58.91% down from the prior year.
  • Receivables for Q4 2025 was $482000.0 at Cardiff Oncology, up from $254000.0 in the prior quarter.
  • Across five years, Receivables topped out at $1.3 million in Q4 2022 and bottomed at $161000.0 in Q2 2023.
  • The 5-year median for Receivables is $466500.0 (2024), against an average of $531200.0.
  • The largest annual shift saw Receivables crashed 70.78% in 2023 before it soared 212.12% in 2024.
  • A 5-year view of Receivables shows it stood at $535000.0 in 2021, then surged by 137.57% to $1.3 million in 2022, then crashed by 30.13% to $888000.0 in 2023, then soared by 32.09% to $1.2 million in 2024, then tumbled by 58.91% to $482000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Receivables are $482000.0 (Q4 2025), $254000.0 (Q3 2025), and $526000.0 (Q2 2025).